Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort.

Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.

Ruxolitinib for myelofibrosis--an update of its clinical effects.

The new landscape of therapy for myelofibrosis.

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

Clearing the path for MPN therapy monitoring.

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing.

Emerging drugs for polycythemia vera.